Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.41 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1683881 | 1.00 | ALDH1A1 (0.46) | ALDH1A1KDM4EHPGDEGFRMAPT | |
| SCHEMBL1683886 | 1.00 | ALDH1A1 (0.46) | ALDH1A1KDM4EHPGDEGFRMAPT | |
| SCHEMBL1683903 | 0.89 | ALDH1A1 (0.47) | ALDH1A1KDM4EHPGDEGFRMAPT | |
| SCHEMBL1683676 | 0.89 | ALDH1A1 (0.47) | ALDH1A1KDM4EHPGDEGFRMAPT | |
| SCHEMBL1683673 | 0.89 | ALDH1A1 (0.47) | ALDH1A1KDM4EHPGDEGFRMAPT | |
| SCHEMBL1683945 | 0.82 | ALDH1A1 (0.49) | ALDH1A1KDM4EHPGDEGFRMAPT | |
| SCHEMBL722625 | 0.82 | ALDH1A1 (0.51) | ALDH1A1KDM4EHPGDMAPTTP53 | |
| SCHEMBL1683665 | 0.77 | MAPT (0.31) | EGFRMAPTPOLB | |
| SCHEMBL724061 | 0.77 | EGFR (0.74) | EGFRMAPTHDAC1HDAC8HDAC6 | |
| SCHEMBL4421791 | 0.77 | EGFR (0.46) | EGFRTP53HSD17B10USP2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10865196-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2020-12-15 | — | — | US | disclosed |
| US-10301285-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190092755-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2019-03-28 | — | — | US | disclosed |
| US-20180093971-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2018-04-05 | — | — | US | disclosed |
| EP-3289876-A1 | COMPOUNDS FOR TREATMENT OF CANCER | University of Tennessee Research Foundation (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-2959900-A1 | COMPOUND FOR TREATMENT OF CANCER | University of Tennessee Research Foundation (US) | 2015-12-30 | — | — | EP | disclosed |
| US-9029408-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140213623-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8592465-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-11-26 | — | — | US | disclosed |
| US-20090326020-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326020-A1 | COMPOUNDS FOR TREATMENT OF CANCER | HCCS, NQO1, CCNY | ALDH1A1 606/4885KDM4E 1473/4885HPGD 116/4885 |
| US-10865196-B2 | Compounds for treatment of cancer | CYP19A1, CYP17A1, SOX18 | ALDH1A1 619/4885KDM4E 260/4885HPGD 661/4885 |
| US-10301285-B2 | Compounds for treatment of cancer | CYP19A1, CYP17A1, SOX18 | ALDH1A1 619/4885KDM4E 260/4885HPGD 661/4885 |
| US-20140213623-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | ALDH1A1 619/4885KDM4E 260/4885HPGD 661/4885 |
| US-20180093971-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | ALDH1A1 619/4885KDM4E 260/4885HPGD 661/4885 |
| US-20190092755-A1 | COMPOUNDS FOR TREATMENT OF CANCER | CYP19A1, CYP17A1, SOX18 | ALDH1A1 619/4885KDM4E 260/4885HPGD 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.